department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Miebo · pharmadog

pharmadog
drugs
Miebo

drug

patient view →

perfluorohexyloctane

Marketedupdated 2mo ago

by $BLCO Bausch & Lomb Corp

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Miebo

generic

perfluorohexyloctane

indication

Keratoconjunctivitis Sicca (Dry Eye)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 43m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

May 18, 2028

~1.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Jun 21, 2037method-of-use (U-1900)US 10507132
Sep 29, 2036formulationUS 11357738
Oct 1, 2035method-of-use (U-1900)US 10576154
Sep 12, 2033method-of-use (U-1900)US 10058615
Sep 12, 2033method-of-use (U-1900)US 10369117
Sep 12, 2033method-of-use (U-1900)US 10449164

FDA exclusivities (1)

May 18, 2028NCENew Chemical Entity (5y)1.9y

🐶 often sniffed alongside

top 1

tagApproval8 co-mentions · 2 sources

Trials studying perfluorohexyloctane

phase4A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracycompletedn=97
phase4SYSTANE® PRO vs. MIEBO™ in Dry Eye Diseaserecruitingn=260
phase2A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Diseaserecruitingn=423
phase4A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wearcompletedn=104
phase3A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Diseasewithdrawn
phase4A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Diseasecompletedn=99
phase4A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.active not recruitingn=216